180465-67-2

Upstream product

• 180465-66-1 C₂₈H₃₇N₃O₆S 
• 10314-98-4 1-benzyloxycarbonylpiperidine-4-carboxylic acid 
• 138163-08-3 N-(benzyloxycarbonyl)piperidine-4-carboxaldehyde 
• 10314-99-5 benzyl 4-(chlorocarbonyl)piperidine-1-carboxylate 
• 100-63-0 phenylhydrazine 
• 122860-33-7 benzyl 4-(hydroxymethyl)piperidine-N-carboxylate 
• 6457-49-4 4-piperidinemethanol 
• 184289-84-7 benzyl 1-(methylsulfonyl)spiro[indoline-3,4’-piperidine]-1‘-carboxylate 
• 167484-18-6 benzyl spiro[indoline-3,4’-piperidine]-1‘-carboxylate 
• 184289-85-8 benzyl spiro[indole-3,4'-piperidine]-1'-carboxylate 
• 178261-41-1 1-(methylsulfonyl)spiro[indoline-3,4’-piperidine] 
• 100-39-0 benzyl bromide 
• 498-94-2 isonipecotic acid 
• 159634-86-3 1-Methanesulfonyl-spiro[indoline-3,4'-piperidine] hydrochloride 

Downstream Products

• 159634-87-4 N-[(R)-[(1,2-Dihydro-1-methanesulfonylspiro[3H-indole-3,4'-piperidin]-1'-yl)carbonyl]-2-(phenylmethyloxy)ethyl]-2-[(1,1-dimethyl-ethoxy)carbonyl]amino-2-methyl-propanamide 
• 159634-47-6 Ibutamoren 
• 191487-52-2 MK-677 
• 851977-26-9 C₂₅H₃₁N₃O₆S₂ 
• 851977-20-3 C₃₀H₄₀N₄O₅S 

Relevant academic research and scientific papers

A facile synthesis of the spiroindoline-based growth hormone secretagogue, MK-677

A facile and improved route for the synthesis of the orally active spiroindoline-based growth hormone secretagogue, MK-677 was described. The key step adopted the Fischer indole/reduction strategy. The preparation of the key intermediates N-protected piperidine carboxaldehyde 5 and the N-Boc-O-benzyl-d-serine (2) are also optimized.

THERAPEUTIC COMPOUNDS AND USES THEREOF

Compounds of formula (I) are described herein The compounds can be used, for example, to modulate growth hormone secretagogue receptor (GHS-R). In some instances, the compounds can be used to treat obesity.

SULFONAMIDES AND USES THEREOF

Compounds of formulas (I), (II), (III), and (IV) and methods of treating disorders by administering a compound of formula (I), (II), (III), or (IV) are described herein. Examples of disorders include neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders.

Serine derived NK1 antagonists 1: The effect of modifications to the serine substituents

A series of novel serine derived NK1 antagonists is described. The effect of variations in the N-benzyl, O-benzyl and serine groups are used to define the elements which are necessary for binding.

Synthesis of the orally active spiroindoline-based Growth Hormone Secretagogue, MK-677

The preparation of the Merck Growth Hormone Secretagogue; MK-677 is described. A Fischer indole/reduction based strategy provides the novel spiroindoline nucleus of this potent compound. This optimized sequence necessitates the isolation of only one intermediate 10 and provides MK-677 in 48% overall yield from isonipecotic acid 3.